A quantitative study of daytime sleepiness induced by carbamazepine and add-on vigabatrin in epileptic patients

Acta Neurol Scand. 1997 Apr;95(4):193-6. doi: 10.1111/j.1600-0404.1997.tb00097.x.

Abstract

Introduction: The clinical relevance of daytime sleepiness associated with carbamazepine (CBZ) and vigabatrin (VGB) was objectively assessed by the multiple sleep latency test (MSLT) and nocturnal sleep recordings.

Material and methods: Twenty-six patients with partial epilepsy and mean monthly seizure frequency of 4, aged 18 to 48 years, receiving chronic monotherapy with CBZ and subsequent VGB addition for 2 months (14 patients), were compared with a group of healthy subjects. Subjective daytime sleepiness was complained by 13 patients on CBZ monotherapy and 9 patients during VGB add-on treatment.

Results: No differences in nocturnal sleep parameters, but significantly shorter daytime sleep latencies at the MSLT, were detected in CBZ-treated patients as compared with healthy controls. Addition of VGB therapy did not further enhance objective daytime sleepiness.

Conclusion: Some sleepiness occurs in chronically CBZ-treated epileptic patients, which can be objectively measured by the MSLT, but it is not aggravated by add-on VGB.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / adverse effects*
  • Anticonvulsants / pharmacology
  • Carbamazepine / adverse effects*
  • Carbamazepine / pharmacology
  • Drug Therapy, Combination
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sleep / drug effects
  • Sleep Stages*
  • Vigabatrin
  • Wakefulness / drug effects
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / pharmacology

Substances

  • Anticonvulsants
  • Carbamazepine
  • gamma-Aminobutyric Acid
  • Vigabatrin